

Express Mail No.: <u>EV 475 141 820 US</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Srivastava Confirmation No.: 1802

Application No.: 09/873,403 Group Art Unit: 1642

Filed: June 4, 2001 Examiner: Christopher H. Yaen

For: COMPLEXES OF ALPHA(2)- Attorney Docket No.: 8449-178-999

MACROGLOBULIN AND ANTIGENIC (CAM #708584-999177)
MOLECULES FOR IMMUNOTHERAPY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97

MAIL STOP RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references EN to EQ listed on the attached form entitled "List of References Cited by Applicant." Copies of references EN to EQ are enclosed herewith.

Identification of the listed references is not meant to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

sheet 2 of 2 Attorney Docket No.: 8449-178-999 Application No.: 09/873,403 Applicant: Srivastava

This supplemental information disclosure statement is being filed along with a Request for Continued Examination under 37 C.F.R. §1.114 in connection with the subject application. Pursuant to 37 C.F.R. §1.97(b), Applicant believes that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if a fee is required, please charge the amount of any such fee to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Date: December 12, 2005

32,60

Adriane M. Antler

JONES DAY 222 East 41st Street

New York, New York 10017

Phone: (212) 901-9028

	Pe		Express M	[ail No.:	EV 475	141 820 US Sheet 1 of 1		
LISTERENCES CITED BY APPLICANT (Use several sheets if necessary)			ATTY. DOCKET NO. 8449-178-999			APPLICATION NO. 09/873,403		
			APPLICANT Srivastava					
			filing date June 4, 2001		GROUP 1642			
		U.S. PATE	NT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
		FOREIGN PA	FENT DOCUMENTS					

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
						YES	NO
			*				-

EN	Rammensee et al. 1995 "MHC ligands and peptide motifs: first listing" <i>Immunogenetics</i> 41:178-228
 EO	Rammensee et al. 1999 "SYFPEITHI: the database for MHC ligands and peptide motifs Immunogenetics 50:213-219
EP	Lovett et al. 1993 "Rubella virus specific cytotoxic T-lymphocyte responses: identification of the capsic as a target of MHC class I-restricted lysis and definition of two epitopes" J. Virology 76:5849-5858
EQ	Thomson et al. 1996 "Recombinant polytopic vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes" J. Immunol. 157:822-826

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.